Key result
Higher Endothelin-1 is linked to ~61% greater kidney event and heart failure risk in diabetic CKD.
Why the study?
With the development of endothelin-1 receptor antagonists, there was interest in whether higher endothelin-1 concentrations are associated with adverse cardio-kidney events in high-risk patients with CKD and type 2 diabetes.
Are higher baseline Endothelin-1 concentrations associated with a greater risk of adverse cardio-kidney events in patients with CKD, T2DM, and anemia?
Cohort (n=997)
Are higher baseline Endothelin-1 concentrations associated with a greater risk of adverse cardio-kidney events in patients with CKD, T2DM, and anemia?
Higher baseline ET-1 concentrations are associated with an increased risk of kidney outcomes, heart failure events, and all-cause death in high-risk patients with CKD, T2DM, and anemia.
Answers are grounded in this paper and cite their sources.
ET-1 may stratify cardio-kidney risk in CKD with T2DM and anemia; hypothesis-generating, does not yet inform practice.
INTRODUCTION: Endothelin-1 (ET-1) is a potent vasoconstrictor and is implicated in the pathogenesis of proteinuria and progressive chronic kidney disease (CKD). With the development of ET-1 receptor antagonists, there is interest in whether higher ET-1 concentrations are associated with a greater risk of adverse cardio-kidney events among high-risk patients, e.g., those with established CKD and type 2 diabetes mellitus (T2DM). METHODS: ET-1 concentrations were measured in a random subset of TREAT (n = 997 [25%] of the original 4,038 patients with CKD, T2DM, and anemia) using an automated ELISA assay on the Ella analyzer (ProteinSimple). We used unadjusted and adjusted Cox regression models to explore the association of baseline serum ET-1 (log-transformed and quartiles) with kidney events (composite of kidney failure or doubling of serum creatinine), heart failure (HF), and cardiovascular and all-cause death. RESULTS: At baseline, mean age was 67 ± 10 years and 56% were female. The mean eGFR was 34 ± 11 mL/min/1.73 m2; median urine protein/creatinine ratio was 0.4 (0.1, 1.7) g/g; median ET-1 was 2.4 (1.9, 3.0) pg/mL. During a median follow-up of 2.4 years, there were 225 kidney events, 99 HF events, 124 cardiovascular deaths, and 188 all-cause deaths. Each log-unit higher ET-1 was associated with a higher adjusted risk of the kidney composite (HR: 1.61; 95% CI: 1.08, 2.39), HF (HR: 2.61; 95% CI: 1.42, 4.81), but not with cardiovascular death (HR: 1.06; 95% CI: 0.65, 1.75) or all-cause death (HR: 1.33; 95% CI: 0.86, 2.04). Compared with the lowest quartile, categorical analyses suggested a higher risk of kidney events (HR 1.69; 95% CI 1.08, 2.64), HF events (HR: 2.35; 95% CI: 1.16, 4.80), and all-cause death (HR: 1.81; 95% CI: 1.09, 3.00) for the highest quartile of ET-1. CONCLUSIONS: Among patients with established CKD, T2DM, and anemia, higher baseline ET-1 was associated with a higher subsequent risk of kidney outcomes, HF events, and all-cause death. Whether higher ET-1 predicts responsiveness to ET receptor antagonism warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Causland et al. (2025) conducted a cohort in Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia (n=997). Baseline serum Endothelin-1 (ET-1) vs. Lower ET-1 concentrations was evaluated on Kidney events (composite of kidney failure or doubling of serum creatinine) (HR 1.61, 95% CI 1.08, 2.39). Among patients with CKD, T2DM, and anemia, each log-unit higher baseline Endothelin-1 was associated with a higher risk of kidney events (HR 1.61; 95% CI 1.08-2.39) and heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: